LNTH vs RPRX
Lantheus Holdings vs Royalty Pharma plc — AI-powered side-by-side comparison
LNTH
Lantheus Holdings
67
Buy
VS
RPRX
Royalty Pharma plc
56
Watch
| Metric | LNTH | RPRX |
|---|
| AI Score |
67
|
56
|
| Price |
$100.63
|
$57.79
|
| P/E Ratio |
23.91×
|
23.98×
|
| ROE |
21.4%
|
11.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
60.1%
|
89.4%
|
| Debt / Equity |
0.44×
|
1.31×
|
| Dividend Yield |
0.0%
|
1.6%
|
| RSI (14) |
42.5
|
49.6
|
| Beta |
-0.057
|
0.425
|
| Expected Upside |
+7.8%
|
—
|
AI Committee View
Current Innellis committee reasoning for LNTH versus RPRX.
LNTH leads by 11 points.
LNTH scores 67/100 (Buy) versus RPRX at 56/100 (Watch).
LNTH Committee View
50% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- 3 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- MACD histogram negative -- bearish momentum — Technical
RPRX Committee View
60% agreement
5 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Value Analyst remains cautious — p/e of 40.9 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- P/E of 40.9 is expensive by classic value standards — Value
- EPS declining -15.9% YoY despite any revenue growth — Growth
- MACD histogram negative -- bearish momentum — Technical